(1996). 18. GST-Akt was expressed from a recombinant baculovirus in Sf9 cells with activated forms of PI3K to achieve kinase activation. GST-Akt was purified from Sf9 lysates by glutathione-Sepharose affinity chromatography. 19. To determine the effects of Akt-mediated phosphorylation on caspase activity, in vitro kinase reactions were performed as described (17) , except that 0.1 mM ATP was substituted for [␥-32 P]ATP. Immobilized Akt was removed by centrifugation, and half the sample (20 l) was incubated with 10 M Ac-DEVDpNA (Alexis) and 2 M purified pro-Casp3 in a final volume of 0.1 ml of caspase buffer (50 mM Hepes, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, and 5 mM dithiothreitol). Caspase activity was based on cleavage of the colorimetric substrate Ac-DEVD-pNA (5) and was normalized relative to Akt-untreated (mock) material. For Casp9 measurements, the addition of pro-Casp3 created a coupled Casp9 3 Casp3 3 DEVD-pNA reaction, because Casp9 does not efficiently cleave DEVD (16) . Activity percent was measured and normalized to mock-treated samples. Anti-HA immune complexes prepared from control-transfected cells and immobilized GST control protein resulted in no significant alterations of caspase activity (4). 20. Pro-Casp9 and Pro-Casp9(C287A) cDNAs, as well as S183A and S196A mutants of these, were expressed with NH 2 -terminal His 6 -tags from pET23b in BL21 cells for production of processed Casp9 and unprocessed Casp9, respectively (16) . Expression was induced with 0.2 mM isopropyl-␤-D-thiogalactopyranoside at OD 600 Х 0.6 to 0.8 and ϳ25°C for 4 hours for the S183A mutant and for 1 hour for the S196A mutant. Proteins were affinity purified by Ni-chelate Sepharose (Pharmacia were transiently transfected with pCMV6-myrAktHA and pcDNA3-FLAG constructs encoding C287A mutants of either pro-Casp9 or pro-Casp9(S196A). Casp9 (wild type) and Casp9(S196A) were isolated by immunoprecipitation using antibody to FLAG, eluted from beads with glycine (pH 3.0), and digested with 0.05 U of V8 protease for 8 hours in 50 mM NH 4 oAc (pH 4.0) at room temperature. The samples were then analyzed by SELDI as described above. An 80-dalton increase in mass indicated that the peptide fragment was phosphorylated. 23. Casp9 mutants were generated by site-directed polymerase chain reaction (PCR) mutagenesis from a human pro-Casp9 cDNA ( V. Dixit) and subcloned into pcDNA3-FLAG, pCMV2-FLAG, or pET23b plasmids. The primer pairs used to generate the S183A and S196A mutants were 5Ј-CCGCACCCGCACTG-GCGCGAACATCGACTGTGAG-3Ј plus 5Ј-CTCACAGT-CGATGT TCGCGCCAGTGCGGGTGCGG-3Ј; and 5Ј-CGGCGTCGCT TCTCCGCGCTGCAT T TCCTGGTGG-3Ј The main inhibitory inputs to spinal cord and brain-stem motoneurons use glycine as a neurotransmitter (1). The ␣ and ␤ transmembrane subunits of glycine receptors (GlyRs) from spinal cord copurify with gephyrin, a 93-kD cytoplasmic protein (2) . Gephyrin binds to the ␤ subunit of the GlyR and to tubulin, thereby linking GlyRs to the cytoskeleton (3) . This interaction appears to be important for the accumulation of GlyRs at synapses, because GlyRs are precisely colocalized with gephyrin at synapses in the brain and spinal cord, gephyrin aggregates GlyRs when coexpressed with them in heterologous cells, and attenuation of gephyrin synthesis with antisense oligonucleotides prevents clustering of GlyRs at synaptic sites on cultured spinal neurons (4-6 ). Molecular cloning of gephyrin (7) revealed unexpected similarity to three Escherichia coli proteins (moeA, moaB, and mog), a Drosophila melanogaster protein (cinnamon), and an Arabidopsis thaliana protein (cnx1), all of which are involved in the synthesis of a molybdenum-containing cofactor essential for the activity of molybdoenzymes (8) . This conservation ( Fig. 1A) suggested that genes of the same bacterial operon may have been joined during evolution to form a multidomain protein that gained a novel function.
We disrupted the gephyrin gene by deleting exon 1 and upstream sequences responsible for initiating transcription and translation (9, 10) .
The mutant allele (Fig. 1B) was transferred to embryonic stem (ES) cells by electroporation, and two successfully targeted clones gave rise to germ-line chimeras (Fig. 1, C 1E ) and protein (Fig. 1F) . However, all geph -/-mice died within 1 day of birth. Thus, gephyrin was dispensable for embryonic development but essential for postnatal survival.
Geph -/-neonates appeared externally normal but failed to suckle and never produced the vocalizations characteristic of normal neonates. In response to mild tactile stimuli, control mice flailed their limbs, whereas geph -/-littermates assumed a rigid, hyperextended posture (Fig. 2,  A and B) . The mutants became increasingly hyperresponsive to tactile stimuli and exhibited apnea (difficulty breathing) by 12 hours after birth. These symptoms are consistent with impairment of inhibitory glycinergic inputs to motoneurons. To test this possibility, we stained spinal cord sections of geph -/-mice and littermate controls with antibodies to synaptic components (11) . In controls, GlyRs and gephyrin are colocalized at inhibitory synapses on motoneuronal somata and primary dendrites (4). In homozygous mutants, synaptic boutons were numerous, but no gephyrin was detected, and GlyRs were diffusely distributed (Fig. 3A) . Likewise, gephyrin and GlyRs were coclustered on subsets of neurons in the brainstem and hypothalamus of control neonates, but gephyrin was undetected and GlyRs were diffusely localized in geph -/-littermates ( Fig. 3B ). High levels of GlyR mRNA and protein persisted in geph -/-brains (Fig. 3 , D and E), indicating that gephyrin was required for GlyR aggregation rather than GlyR synthesis. No difference was detected between mutants and controls in the size or distribution of glutamate receptor clusters, in the synaptic localization of their putative clustering proteins of the PSD-95/SAP-90 family (12) , or in the overall morphology of the spinal cord and brain (Fig. 3, A and C) . Thus, defects were specific for GlyRs.
The motor defects seen in geph -/-mice occurred earlier and were more severe than those observed in mutant mice that lack the GlyR ␣1 subunit or have reduced levels of the GlyR ␤ subunit (13) . This difference might be due to a more drastic reduction of synaptic GlyR levels in geph -/-mice, but the sequence similarity noted above (7, 8) raised the possibility that gephyrin might also be required for molybdenum metabolism. In fact, humans born with autosomal recessive molybdenum cofactor deficiency exhibit severe neurological defects that resemble those seen in geph -/-mice, such as hypertonicity, myoclonus, and difficulty in feeding (14) . Molybdenum cofactor deficiency is diagnosed in humans by demonstrating coordinate loss of activity of two distinct molybde- num-containing enzymes, sulfite oxidase and xanthine dehydrogenase, which are ubiquitously expressed (14) . We readily detected sulfite oxidase activity (15) in livers of control neonates, but not in livers of geph -/-mice (Fig.  4A) . Xanthine dehydrogenase is not present in liver at birth even in controls, but is expressed in intestine. Xanthine dehydrogenase is also abundant in milk (16), so we avoided this source of contamination by assaying fetal intestine (17) and detected no activity in the homozygous mutants (Fig. 4B) . As a control, we assayed the activity of an unrelated metabolic enzyme, lactate dehydrogenase, and the abundance of sulfite oxidase mRNA (18) . Neither of these parameters differed among genotypes (Fig. 4, C and D) . Thus, gephyrin appears to be essential for molybdenum cofactor biosynthesis in mice.
In view of these defects in molybdoenzyme activity, we considered the possibility that the neurological symptoms of geph -/-mice were secondary to their metabolic disorder rather than to disruption of glycinergic synapses. Two findings favor this possibility. First, patients with mutations in the sulfite oxidase gene are symptomatically similar to patients that lack molybdenum cofactor, suggesting that neurological defects in both groups result from sulfite toxicity (19) . Second, glycinergic transmission may be excitatory rather than inhibitory in embryos (20) . The developmental stage at which activation of GlyR becomes inhibitory is around birth in rats (21) but is unknown in mice. If it were postnatal, interference with glycinergic transmission might have a calming rather than a stimulatory effect on motor behavior, and the observed hyperresponsiveness of geph -/-mice could reflect sulfite toxicity. To address these issues, we injected neonatal mice with strychnine, a specific antagonist of GlyR (21) . Like gephyrin mutants, strychnine-intoxicated neonates assumed a rigid, hyperextended posture in response to mild tactile stimuli (Fig.  2C) . Thus, glycinergic transmission appeared to be predominantly inhibitory at birth, and blockade of glycinergic transmission in the absence of interference with molybdenum metabolism phenocopied the motor symptoms of gephyrin deficiency. Motor defects in geph -/-mice-and by implication, in molybdenum cofactor-deficient humans-may therefore result from both impaired inhibitory neurotransmission and impaired molybdoenzyme activity.
Our results demonstrate that gephyrin is essential for the synaptic clustering of GlyRs in vivo. Gephyrin may play a role at inhibitory synapses similar to that played by the clustering protein rapsyn at neuromuscular junctions (22) . A second role of gephyrin is in synthesis of molybdenum cofactor. Homologous proteins have been described in other phyla (8) , but no components of the molybdenum cofactor synthetic pathway have been identified in vertebrates. This peculiar pleiotropy raises four interesting possibilities. First, mutations in the gephyrin gene may underlie some cases of autosomal recessive human molybdenum cofactor deficiency. Second, some neurological symptoms now attributed to molybdoenzyme inactivity in humans may actually reflect a lack of receptor accumulation at inhibitory synapses. Third, although some cases of hyperekplexia (startle disease or stiff baby syndrome) are due to mutations in the GlyR (23), others might result from mutations of gephyrin, in which case some of the symptoms could reflect molybdenum insufficiency. Finally, activation or aggregation of GlyRs might modulate the ability of gephyrin to promote molybdopterin biosynthesis, thus resulting in a functional link between molybdoenzymes and inhibitory neurotransmission. Fumagillin-based drugs inhibit MetAP-2 but not MetAP-1, and the three-dimensional structure also indicates the likely determinants of this specificity. The structural basis for fumagillin's potency and specificity forms the starting point for structure-based drug design.
Structure of Human Methionine
Angiogenesis, the growth of new blood vessels, is a pathological determinant in tumor progression, diabetic retinopathy, and rheumatoid arthritis (1). The serendipitous discovery that fumagillin, a fungal metabolite, potently inhibits angiogenesis initiated the systematic development of small molecule angiogenesis inhibitors (2, 3) (Fig. 1) . One semisynthetic derivative of fumagillin, TNP-470, is in clinical trials as an anticancer agent ( Fig. 1) (3, 4) . Fumagillinbased affinity reagents identified MetAP-2 as the specific cellular target of fumagillin, and this specificity was confirmed with genetically altered yeast strains (5, 6) . The correlation between the antiproliferative activity of several fumagillin analogs with their ability to inhibit MetAP-2 activity in vitro suggests that MetAP-2 is the physiologically relevant target of fumagillin-based therapeutic agents (6) . This suggestion is strengthened by a recent report that human endothelial cells are especially sensitive to fumagillin and that proliferation of these cells can be blocked by human MetAP-2 antisense oligonucleotides (7). MetAPs, which 
